ArticleJournal of clinical practice and research2024
A Disease Course of the Oldest Crohn's Disease Patient Reported in Türkiye.
Article in Journal of clinical practice and research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Crohn's disease is an inflammatory bowel disease predominantly seen in young people. However, owing to its bimodal age distribution, it reaches its second peak between the ages of 50-70. The treatment of elderly Crohn's disease patients (described as over 60 years of age) remains controversial. Very few studies have described the treatment of elderly patients in our country. Case Report: We present the management of the oldest patient ever identified with Crohn's disease in our country. In light of recent evidence, the optimal agent for treating fragile patients and those with a history of infections is vedolizumab. However, vedolizumab is not reimbursed as a primary treatment in our country. Therefore, we treated the patient with corticosteroids and azathioprine. Conclusion: We have determined that the use of corticosteroids for induction of remission and azathioprine for maintenance of remission is safe, on a case-by-case basis, within the framework of conditions in our country.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.